Ruggedness of Visible-Residue Limits for Cleaning (Part II) - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Ruggedness of Visible-Residue Limits for Cleaning (Part II)
The author challenges current detection methodologies.


Pharmaceutical Technology
Volume 35, Issue 3, pp. 122-128

Conclusion

The presentation order of the coupons appears to have no effect on the determination of VRLs. Both a sequential presentation from high to low concentration and a random presentation resulted in the same conclusions for VRL levels, thus confirming the ruggedness of the VRL determination.

Richard Forsyth is a senior consultant with Hyde Engineering + Consulting, 6260 Lookout Rd., Suite 120, Boulder, CO 80301, tel. 303.530.4526, fax 303.581.0839,
.

Submitted: Oct. 1, 2010. Accepted: Dec. 1, 2010.

References

1. R.J. Forsyth and V. Van Nostrand, Pharm. Technol. 28 (10), 58–72 (2004).

2. R.J. Forsyth and V. Van Nostrand, Pharm. Technol. 29 (10), 152–161 (2005).

3. R.J. Forsyth and V. Van Nostrand, Pharm. Technol. 29 (4), 134–140 (2005).

4. R.J. Forsyth, J.L. Hartman, and V. Van Nostrand, Pharm. Technol. 31 (4), 134–140 (2007).

5. R.J. Forsyth et al., Pharm. Technol. 30 (11), 90–100 (2006).

6. R.J. Forsyth, Pharm. Technol. 33 (3), 102–111 (2009).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here